Literature DB >> 11678840

Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma.

A Zahedi1, G L Booth, H S Smyth, W E Farrell, R N Clayton, S L Asa, S Ezzat.   

Abstract

The pathogenetic mechanisms underlying pituitary tumorigenesis are largely unknown. Previous reports have suggested that aggressive pituitary adenomas and/or carcinomas may be associated with genetic alterations that are distinct from those responsible for the more common and less aggressive pituitary adenomas. Here, we describe the clonal composition of a pituitary carcinoma, its recurrence and its metastasis. The samples studied were from a 48-year-old woman who presented with recurrent Cushing's syndrome. During the 8-year course of her disease, she had an ACTH-producing pituitary carcinoma requiring two transsphenoidal procedures and resection of a metastatic cervical lymph node. Her disease remained active despite surgical resection, external beam irradiation and medical treatment with ketoconazole. Ultimately, bilateral adrenalectomy was performed to control the hypercortisolism. Morphological and immunohistochemical studies revealed that the primary and recurrent pituitary tumours and the metastatic lesion were an endocrine tumour with ACTH and growth hormone immunoreactivity. Primary, recurrent and metastatic tumour DNAs were analysed for X-chromosome inactivation and loss of heterozygosity (LOH) at several microsatellite loci on chromosomes 9,10, 11, 13 and 22. All three lesions were monoclonal in composition as suggested by the pattern of X chromosome inactivation of the PGK-1 allele. Moreover, the primary, recurrent and metastatic lesions demonstrated LOH at the microsatellite allelic markers PYGM and D10S217. In contrast, however, the metastatic lesion showed a loss-to-retention pattern at two distinct loci (IFNA and D22S156) compared to the primary and recurrent pituitary tumours. These findings, while consistent with a clonal composition of the primary and metastatic pituitary lesions, show each clone to be distinct. This is the first description of a metastatic pituitary carcinoma with a distinct clonal composition from its primary source.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678840     DOI: 10.1046/j.1365-2265.2001.01322.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

Review 1.  Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Authors:  Frederick Yoo; Edward C Kuan; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

2.  MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Authors:  Fateme Salehi; Bernd W Scheithauer; Johann M Kros; Queenie Lau; Michael Fealey; Dana Erickson; Kalman Kovacs; Eva Horvath; Ricardo V Lloyd
Journal:  J Neurooncol       Date:  2011-02-11       Impact factor: 4.130

Review 3.  Pituitary carcinoma: diagnosis and treatment.

Authors:  M Beatriz S Lopes; Bernd W Scheithauer; David Schiff
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

4.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

5.  Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy.

Authors:  Abel Po-Hao Huang; Shih-Hung Yang; Chi-Cheng Yang; Meng-Fai Kuo; Mu Zon Wu; Yong-Kwang Tu
Journal:  J Neurooncol       Date:  2008-07-12       Impact factor: 4.130

Review 6.  Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.

Authors:  Agatha A van der Klaauw; Tina Kienitz; Christian J Strasburger; Johannes W A Smit; Johannes A Romijn
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

7.  Extremely late development of pituitary carcinoma after surgery and radiotherapy.

Authors:  Eberval Gadelha Figueiredo; Wellingson Silva Paiva; Manoel Jacobsen Teixeira
Journal:  J Neurooncol       Date:  2008-11-26       Impact factor: 4.130

Review 8.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

9.  A tumour with a neuroendocrine and papillary serous component: two or a pair?

Authors:  S Van Eeden; P M Nederlof; B G Taal; G J A Offerhaus; M-L F Van Velthuysen
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

10.  Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy.

Authors:  Rohan R Lall; Stephen F Shafizadeh; Kyung-Hwa Lee; Qinwen Mao; Minesh Mehta; Jeffrey Raizer; Bernard R Bendok; James P Chandler
Journal:  Surg Neurol Int       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.